HPC6
MCID: PRS136
MIFTS: 33

Prostate Cancer, Hereditary, 6 (HPC6)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 6

MalaCards integrated aliases for Prostate Cancer, Hereditary, 6:

Name: Prostate Cancer, Hereditary, 6 57 13 70
Prostate Cancer, Susceptibility to 57
Prostate Cancer 57
Hpc6 57

Classifications:



External Ids:

OMIM® 57 609558
MedGen 41 C1836005
UMLS 70 C1836005

Summaries for Prostate Cancer, Hereditary, 6

MalaCards based summary : Prostate Cancer, Hereditary, 6, also known as prostate cancer, susceptibility to, is related to prostate cancer and prostate cancer, hereditary, 1. An important gene associated with Prostate Cancer, Hereditary, 6 is HPC6 (Prostate Cancer, Susceptibility To). The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node.

More information from OMIM: 609558

Related Diseases for Prostate Cancer, Hereditary, 6

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1213)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 12.3
2 prostate cancer, hereditary, 1 11.7
3 prostate cancer, hereditary, 2 11.7
4 prostate cancer, hereditary, 13 11.6
5 prostate cancer, hereditary, 12 11.6
6 prostate cancer, hereditary, 4 11.6
7 prostate cancer, hereditary, 11 11.6
8 pachyonychia congenita 3 11.5
9 prostate cancer, hereditary, 8 11.5
10 prostate cancer, hereditary, 3 11.5
11 prostate cancer, hereditary, 9 11.4
12 prostate cancer, hereditary, x-linked 1 11.4
13 prostate cancer/brain cancer susceptibility 11.4
14 prostatic hypertrophy 11.4
15 prostate cancer, hereditary, 7 11.4
16 prostatic hyperplasia, benign 11.4
17 prostatic adenoma 11.4
18 prostate cancer, hereditary, 10 11.3
19 prostate cancer, hereditary, 15 11.3
20 prostate cancer, hereditary, 14 11.3
21 prostate disease 11.3
22 prostate cancer, hereditary, x-linked 2 11.3
23 prostate cancer, hereditary, 5 11.3
24 suppression of tumorigenicity 12 11.2
25 impotence 11.2
26 diethylstilbestrol syndrome 11.1
27 radiation proctitis 11.1
28 hereditary breast ovarian cancer syndrome 11.1
29 prostate cancer aggressiveness quantitative trait locus on chromosome 19 11.1
30 breast-ovarian cancer, familial 2 11.1
31 alopecia, androgenetic, 1 11.1
32 breast-ovarian cancer, familial 1 11.0
33 prostate sarcoma 11.0
34 gastric cancer, hereditary diffuse 11.0
35 severe combined immunodeficiency 11.0
36 prostatitis 11.0
37 sexual disorder 10.9
38 neutropenia 10.9
39 adenocarcinoma 10.9
40 hypoxia 10.9
41 bladder cancer 10.9
42 bone disease 10.9
43 proctitis 10.8
44 body mass index quantitative trait locus 1 10.8
45 bone resorption disease 10.8
46 insulin-like growth factor i 10.8
47 hypogonadism 10.8
48 47,xyy 10.8
49 pik3ca-related overgrowth syndrome 10.8
50 bone mineral density quantitative trait locus 8 10.8

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 6:



Diseases related to Prostate Cancer, Hereditary, 6

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 6

Clinical features from OMIM®:

609558 (Updated 20-May-2021)

Drugs & Therapeutics for Prostate Cancer, Hereditary, 6

Drugs for Prostate Cancer, Hereditary, 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 760)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
3
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
4
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
9
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
14
Ondansetron Approved Phase 4 99614-02-5 4595
15
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
16
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
17
Desflurane Approved Phase 4 57041-67-5 42113
18
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
19
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
20
Denosumab Approved Phase 4 615258-40-7
21
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
22
Pamidronate Approved Phase 4 40391-99-9 4674
23
Abarelix Approved, Investigational, Withdrawn Phase 4 183552-38-7 16131215
24
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
25
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
26 Phosphodiesterase 5 Inhibitors Phase 4
27 Analgesics Phase 4
28 5-alpha Reductase Inhibitors Phase 4
29 Neurotransmitter Agents Phase 4
30 Psychotropic Drugs Phase 4
31 Anti-Anxiety Agents Phase 4
32 Excitatory Amino Acid Antagonists Phase 4
33 Anesthetics, Local Phase 4
34 Plasma Substitutes Phase 4
35 Blood Substitutes Phase 4
36 Angelica Phase 4
37 Dong Quai Phase 4
38 Analgesics, Opioid Phase 4
39 Hypnotics and Sedatives Phase 4
40 Anesthetics, Intravenous Phase 4
41 GABA Modulators Phase 4
42 Dopamine Antagonists Phase 4
43 Antipsychotic Agents Phase 4
44 Adrenergic alpha-Agonists Phase 4
45 Ophthalmic Solutions Phase 4
46 Adrenergic Agonists Phase 4
47 Brimonidine Tartrate Phase 4 70359-46-5
48 Anesthetics, Inhalation Phase 4
49 Hydroxyethyl Starch Derivatives Phase 4
50 Anesthetics, Dissociative Phase 4

Interventional clinical trials:

(show top 50) (show all 4373)
# Name Status NCT ID Phase Drugs
1 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
2 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
3 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
4 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
5 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
6 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
7 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
8 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
9 Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
10 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
11 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
12 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
13 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
14 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
15 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
16 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
17 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
18 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
19 The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men Completed NCT00859027 Phase 4 risedronate;Placebo risedronate oral tablet
20 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
21 Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy Completed NCT01083199 Phase 4
22 Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test Completed NCT01296672 Phase 4 Finasteride;Placebo
23 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
24 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function After Robot-assisted Prostatectomy Completed NCT01547416 Phase 4 epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose;no epidural drug administered
25 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
26 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
27 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
28 A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) Completed NCT02485691 Phase 4 cabazitaxel XRP6258;enzalutamide;abiraterone acetate;prednisone
29 Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
30 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
31 A Prospective Study to Evaluate the Effect of Preoperative Topical Brimonidine Tartrate 0.2% (Allergan, Irvine, CA) on Intraocular Pressure (IOP) of Patients Undergoing Robot-assisted Laparoscopic Prostatectomy (RALP) Completed NCT02818816 Phase 4 brimonidine tartrate 0.2%
32 Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study Completed NCT02773251 Phase 4 hyaluronic acid-carboxymethylcellulose
33 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
34 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
35 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
36 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption & Anxiety & Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill
37 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
38 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
39 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
40 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
41 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
42 The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
43 The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients Completed NCT04776889 Phase 4 Rosuvastatin 20mg
44 A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in CRPC Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus ADT Completed NCT02918968 Phase 4 Enzalutamide;Flutamide
45 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery Completed NCT02149628 Phase 4 propofol;Desflurane
46 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
47 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
48 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Completed NCT01753297 Phase 4 Triptorelin 11.25 mg
49 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
50 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin

Search NIH Clinical Center for Prostate Cancer, Hereditary, 6

Genetic Tests for Prostate Cancer, Hereditary, 6

Anatomical Context for Prostate Cancer, Hereditary, 6

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 6:

40
Prostate, Bone, Lymph Node, Breast, T Cells, Bone Marrow, Lung

Publications for Prostate Cancer, Hereditary, 6

Articles related to Prostate Cancer, Hereditary, 6:

# Title Authors PMID Year
1
Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. 57
20631155 2010
2
Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. 57
18066601 2008
3
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. 57
17478474 2007
4
Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. 57
17047086 2006
5
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 57
15988677 2005
6
Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. 61
21883825 2012
7
Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. 61
17700570 2007
8
Genetic linkage analysis of prostate cancer families to Xq27-28. 61
11096277 2001
9
Intention to be tested for prostate cancer risk among African-American men. 61
11142417 2000

Variations for Prostate Cancer, Hereditary, 6

Expression for Prostate Cancer, Hereditary, 6

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 6.

Pathways for Prostate Cancer, Hereditary, 6

GO Terms for Prostate Cancer, Hereditary, 6

Sources for Prostate Cancer, Hereditary, 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....